Data_Sheet_1_Serum-Urine Matched Metabolomics for Predicting Progression of Henoch-Schonlein Purpura Nephritis.docx
Henoch-Schonlein purpura nephritis (HSPN) is a common glomerulonephritis secondary to Henoch-Schonlein purpura (HSP) that affects systemic metabolism. Currently, there is a rarity of biomarkers to predict the progression of HSPN. This work sought to screen metabolic markers to predict the progression of HSPN via serum-urine matched metabolomics. A total of 90 HSPN patients were enrolled, including 46 HSPN (+) patients with severe kidney damage (persistent proteinuria >0.3 g/day) and 44 HSPN (–) patients without obvious symptoms (proteinuria < 0.3 g/day). Untargeted metabolomics was determined by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS). A total of 38 and 50 differential metabolites were, respectively, identified in serum and urine from the comparison between HSPN (+) and HSPN (–) patients. Altered metabolic pathways in HSPN (+) mainly included glycerophospholipid metabolism, pyruvate metabolism, and citrate cycle. A panel of choline and cis-vaccenic acid gave areas under the curve of 92.69% in serum and 72.43% in urine for differential diagnosis between HSPN (+) and HSPN (–). In addition, the two metabolites showed a significant association with clinical indices of HSPN. These results suggest that serum-urine matched metabolomics comprehensively characterized the metabolic differences between HSPN (+) and HSPN (–), and choline and cis-vaccenic acid could serve as biomarkers to predict HSPN progression.
History
References
- https://doi.org//10.1016/j.intimp.2020.106229
- https://doi.org//10.2340/00015555-2733
- https://doi.org//10.2215/CJN.06710810
- https://doi.org//10.1016/j.autrev.2015.02.003
- https://doi.org//10.1186/s12014-020-09274-x
- https://doi.org//10.1007/s10067-017-3972-3
- https://doi.org//10.1038/nrm.2016.25
- https://doi.org//10.2215/CJN.09480817
- https://doi.org//10.3390/nu11071664
- https://doi.org//10.1016/j.jpba.2017.10.037
- https://doi.org//10.1016/j.lfs.2020.118160
- https://doi.org//10.3390/biomedicines8070222
- https://doi.org//10.14670/HH-26.1599
- https://doi.org//10.2215/CJN.10010818
- https://doi.org//10.1016/j.tranon.2019.10.015
- https://doi.org//10.1074/jbc.M405147200
- https://doi.org//10.1038/ki.1996.247
- https://doi.org//10.1038/ki.1993.66
- https://doi.org//10.3390/nu11040722
- https://doi.org//10.1186/s12944-019-1093-5
- https://doi.org//10.1161/CIRCULATIONAHA.119.045561
- https://doi.org//10.1016/j.juro.2008.07.017
- https://doi.org//10.1152/ajprenal.00536.2012
- https://doi.org//10.1152/ajprenal.00082.2003
- https://doi.org//10.1161/CIRCRESAHA.116.305360
- https://doi.org//10.1016/j.plefa.2012.02.009
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Medical Genetics (excl. Cancer Genetics)
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Primary Health Care
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care